Are diabetic metabolic compensation and CA19.9 really correlated?

International Journal of Biological Markers

Volumn 11, Issue 4, 1996, Pages 207-210

  Banfi, G ^a   Ardemagni, A ^a   Bravi, S ^a   Pacchioni, M ^a   Bonini, P ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

CA19.9; Diabetes; Glycated hemoglobin; Pancreatic carcinoma

Indexed keywords

BIOCHEMICAL MARKER; CA 19-9 ANTIGEN; GLYCOSYLATED HEMOGLOBIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CARCINOMA;

FELIS CATUS;

EID: 0030479690     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089601100405     Document Type: Article

References (19)

1. Gordis L, Gold EB. Epidemiology of pancreatic cancer. World J Surg 1984; 8: 808-20.
2. Berrino F. Registro Tumori Lombardia. Incidenza dei tumori e causa di morte in Lombardia. Notizie Sanità n. 10, Milano, Regione Lombardia, 1987.
3. Clark CG, Mitchell PEG. Diabetes mellitus and primary carcinoma of the pancreas. BMJ 1961; 2: 1259-62.
4. Karmody AJ, Kyle J. The association between carcinoma of the pancreas and diabetes mellitus. Br J Surg 1969; 56: 362-4.
5. Norell S, Ahlbom A, Erwald R, et al. Diabetes, gall stone disease, and pancreatic cancer. Br J Cancer 1986; 54: 377-8.
6. Cuzick J, Babiker AG. Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. Int J Cancer 1989; 43: 415-21.
7. Gullo L, Pezzilli R, Morselli-Labate AM, and the Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Engl J Med, 1994; 331 81-4.
8. Green A, Jensen OM. Frequency of cancer among insulin-treated diabetic patients in Denmark. Diabetologia 1985; 28: 128-30.
9. Steinberg WM, Gelfand R, Anderson KK. et al. Comparison of the sensitivity and specificity of the CA19.9 and carcinoembyronic antigen assay in detecting cancer of the pancreas. Gastroenterology 1986; 90: 343-9.
10. Banfi G, Zerbi A, Pastori S, Parolini D, Di Carlo V, Bonini PA. Behavior of tumor markers CA 19.9. CA195, CAM43, CA242 and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 1993; 39: 420-3.
11. Benhamou PY, Vuillez JP, Halimi S, Meffre G, Bachelot I. Influence of metabolic disturbances of diabetes mellitus on serum CA19.9 tumor marker. Diabete Metab 1991; 17: 39-43.
12. Magnani L, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastro-intestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19.9 in the sera of patients as a mucin. Cancer Res 1983; 43: 5489-92.
13. Zucchelli GC, Pilo A, Chiesa MR. Growing use of nonisotopic CA 19.9 immunoassays increases between laboratory variability. Clin Chem 1993; 39: 309-11.
14. Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody defined tumor marker CA19.9. Clin Chem 1983; 29: 549-52.
15. Kessler II. Cancer mortality among diabetics. J Natl Cancer Inst 1970; 44: 673-86.
16. Friedman GD, van der Eeden SK. Risk factors for pancreatic cancer: an exploratory study. Int J Epidemiol 1993; 22: 30-7.
17. Arawaka Y, Ariga H, Kano M, Matsuo Y, Honda T, Morita K. Determination and significance of a new carbohydrate antigen CA19.9 in digestive system cancers. Jpn J Med 1985; 24: 121-30.
18. Ruibal A, Encabo G, Gefaell R, Martinez-Miralles E, Fort JM, Fernandez-Llamazares J. Clinical interest of seric CA19.9 determination in differential diagnosis of patients with peptic ulcers and gastric cancer. Bull Cancer 1983; 70: 438-40.
19. Ritts RE, Del Villano BC, Go VL. Herberman RB, Klug TL, Zurawski R. Initial clinical evaluation of an immunoradiometric assay for CA 19.9 using the NCL serum bank. Int J Cancer 1984; 33: 339-45.